Scaffolding Protein SPIDR/KIAA0146 Connects the Bloom Syndrome Helicase with Homologous Recombination Repair
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Variant Requirements for DNA Repair Proteins in Cancer Cell Lines That Use
Variant requirements for DNA repair proteins in cancer cell lines that use alternative lengthening of telomere mechanisms of elongation DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Alaina Rae Martinez Biomedical Sciences Graduate Program The Ohio State University 2016 Dissertation Committee: Dr. Jeffrey D. Parvin, Advisor Dr. Joanna Groden Dr. Amanda E. Toland Dr. Kay F. Huebner Copyright by Alaina Rae Martinez 2016 Abstract The human genome relies on DNA repair proteins and the telomere to maintain genome stability. Genome instability is recognized as a hallmark of cancer, as is limitless replicative capacity. Cancer cells require telomere maintenance to enable this uncontrolled growth. Most often telomerase is activated, although a subset of human cancers depend on recombination-based mechanisms known as Alternative Lengthening of Telomeres (ALT). ALT depends invariably on recombination and its associated DNA repair proteins to extend telomeres. This study tested the hypothesis that the requirement for those requisite recombination proteins include other types of DNA repair proteins. These functions were tested in ALT cell lines using C-circle abundance as a marker of ALT. The requirement for homologous recombination proteins and other DNA repair proteins varied between ALT cell lines compared. Several proteins essential for homologous recombination were dispensable for C-circle production in some ALT cell lines, while proteins grouped into excision DNA repair processes were required for C- circle production. The MSH2 mismatch repair protein was required for telomere recombination by intertelomeric exchange. In sum, our study suggests that ALT proceeds by multiple mechanisms that differ between human cancer cell lines and that some of these depend on DNA repair proteins not associated with homologous recombination pathways. -
Structure and Function of the Human Recq DNA Helicases
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2005 Structure and function of the human RecQ DNA helicases Garcia, P L Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-34420 Dissertation Published Version Originally published at: Garcia, P L. Structure and function of the human RecQ DNA helicases. 2005, University of Zurich, Faculty of Science. Structure and Function of the Human RecQ DNA Helicases Dissertation zur Erlangung der naturwissenschaftlichen Doktorw¨urde (Dr. sc. nat.) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultat¨ der Universitat¨ Z ¨urich von Patrick L. Garcia aus Unterseen BE Promotionskomitee Prof. Dr. Josef Jiricny (Vorsitz) Prof. Dr. Ulrich H ¨ubscher Dr. Pavel Janscak (Leitung der Dissertation) Z ¨urich, 2005 For my parents ii Summary The RecQ DNA helicases are highly conserved from bacteria to man and are required for the maintenance of genomic stability. All unicellular organisms contain a single RecQ helicase, whereas the number of RecQ homologues in higher organisms can vary. Mu- tations in the genes encoding three of the five human members of the RecQ family give rise to autosomal recessive disorders called Bloom syndrome, Werner syndrome and Rothmund-Thomson syndrome. These diseases manifest commonly with genomic in- stability and a high predisposition to cancer. However, the genetic alterations vary as well as the types of tumours in these syndromes. Furthermore, distinct clinical features are observed, like short stature and immunodeficiency in Bloom syndrome patients or premature ageing in Werner Syndrome patients. Also, the biochemical features of the human RecQ-like DNA helicases are diverse, pointing to different roles in the mainte- nance of genomic stability. -
A Novel Breast Cancer ^ Associated BRIP1 (FANCJ/BACH1) Germ- Line Mutation Impairs Protein Stability and Function
Cancer Prevention and Susceptibility A Novel Breast Cancer ^ Associated BRIP1 (FANCJ/BACH1)Germ- line Mutation Impairs Protein Stability and Function Arcangela De Nicolo,1MariellaTancredi,4 Grazia Lombardi,4 Cristina Chantal Flemma,4 Serena Barbuti,4 Claudio Di Cristofano,4 Bijan Sobhian,1Generoso Bevilacqua,4 Ronny Drapkin,2,3 andMariaAdelaideCaligo4 Abstract Purpose: BRCA1-interacting protein 1 (BRIP1; FANCJ/BACH1), which encodes a DNA helicase that interacts with BRCA1, has been suggested to be a low-penetrance breast cancer predispos- ing gene.We aimed to assess whether BRIP1 mutations contribute to breast cancer susceptibility in our population and, if so, to investigate the effect of such mutation(s) on BRIP1function. Experimental Design: A series of49 breast/ovarian cancer families, devoid ofa BRCA1/ BRCA2 mutation, were screened for BRIP1 mutations. Functional analyses, including coimmuno- precipitation and stability assays, were employed to further characterize a previously unreported variant. Results: Five sequence alterations were identified, of which four had been already described. Herein, we report a novel BRIP1 germ-line mutation identified in a woman with early-onset breast cancer. The mutation consists ofa 4-nucleotide deletion (c.2992-2995delAAGA) in BRIP1 exon 20 that causes a shift in the reading frame, disrupts the BRCA1-binding domain of BRIP1, and creates a premature stop codon. Functional analysis ofthe recombinant mutant protein in transfected cells showed that the truncation interferes with the stability of the protein and with its ability to interact with BRCA1. Loss ofthe wild-type BRIP1 allele with retention ofthe mutated one was observed in the patient’s breast tumor tissue. Conclusions: These results, by showing that the newly identified BRIP1 c.2992-2995delAAGA mutation is associated with instability and functional impairment of the encoded protein, provide further evidence of a breast cancer ^ related role for BRIP1. -
Open Full Page
CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Michael F. Walsh1, Vivian Y. Chang2, Wendy K. Kohlmann3, Hamish S. Scott4, Christopher Cunniff5, Franck Bourdeaut6, Jan J. Molenaar7, Christopher C. Porter8, John T. Sandlund9, Sharon E. Plon10, Lisa L. Wang10, and Sharon A. Savage11 Abstract DNA repair syndromes are heterogeneous disorders caused by around the world to discuss and develop cancer surveillance pathogenic variants in genes encoding proteins key in DNA guidelines for children with cancer-prone disorders. Herein, replication and/or the cellular response to DNA damage. The we focus on the more common of the rare DNA repair dis- majority of these syndromes are inherited in an autosomal- orders: ataxia telangiectasia, Bloom syndrome, Fanconi ane- recessive manner, but autosomal-dominant and X-linked reces- mia, dyskeratosis congenita, Nijmegen breakage syndrome, sive disorders also exist. The clinical features of patients with DNA Rothmund–Thomson syndrome, and Xeroderma pigmento- repair syndromes are highly varied and dependent on the under- sum. Dedicated syndrome registries and a combination of lying genetic cause. Notably, all patients have elevated risks of basic science and clinical research have led to important in- syndrome-associated cancers, and many of these cancers present sights into the underlying biology of these disorders. Given the in childhood. Although it is clear that the risk of cancer is rarity of these disorders, it is recommended that centralized increased, there are limited data defining the true incidence of centers of excellence be involved directly or through consulta- cancer and almost no evidence-based approaches to cancer tion in caring for patients with heritable DNA repair syn- surveillance in patients with DNA repair disorders. -
Analysis of and Fanconi Anemia Genes in -Negative Spanish Breast Cancer Families María J
Analysis of and Fanconi Anemia genes in -negative Spanish breast cancer families María J. García, Victoria Fernández, Ana Osorio, Alicia Barroso, Gemma Llort, Conxi Lázaro, Ignacio Blanco, Trinidad Caldés, Miguel Hoya, Teresa Ramón y Cajal, et al. To cite this version: María J. García, Victoria Fernández, Ana Osorio, Alicia Barroso, Gemma Llort, et al.. Analysis of and Fanconi Anemia genes in -negative Spanish breast cancer families. Breast Cancer Research and Treatment, Springer Verlag, 2008, 113 (3), pp.545-551. 10.1007/s10549-008-9945-0. hal-00478320 HAL Id: hal-00478320 https://hal.archives-ouvertes.fr/hal-00478320 Submitted on 30 Apr 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Breast Cancer Res Treat (2009) 113:545–551 DOI 10.1007/s10549-008-9945-0 EPIDEMIOLOGY Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families Marı´a J. Garcı´a Æ Victoria Ferna´ndez Æ Ana Osorio Æ Alicia Barroso Æ Gemma LLort Æ Conxi La´zaro Æ Ignacio Blanco Æ Trinidad Calde´s Æ Miguel de la Hoya Æ Teresa Ramo´n y Cajal Æ Carmen Alonso Æ Marı´a-Isabel Tejada Æ Carlos San Roma´n Æ Luis Robles-Dı´az Æ Miguel Urioste Æ Javier Benı´tez Received: 12 February 2008 / Accepted: 12 February 2008 / Published online: 27 February 2008 Ó Springer Science+Business Media, LLC. -
The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice
G C A T T A C G G C A T genes Review The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice Luigia Stefania Stucci 1,* , Valeria Internò 1 , Marco Tucci 1,2 , Martina Perrone 1, Francesco Mannavola 1 , Raffaele Palmirotta 3 and Camillo Porta 1 1 Division of Medical Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari ‘Aldo Moro’, A.O.U. Consorziale Policlinico di Bari, 70121 Bari, Italy; [email protected] (V.I.); [email protected] (M.T.); [email protected] (M.P.); [email protected] (F.M.); [email protected] (C.P.) 2 National Cancer Research Center, Tumori Institute IRCCS Giovanni Paolo II, 70121 Bari, Italy 3 Interdisciplinary Department of Medicine, Section of Sciences and Technologies of Laboratory Medicine, University of Bari, 70121 Bari, Italy; [email protected] * Correspondence: [email protected] Abstract: Molecular alterations of the Ataxia-telangiectasia (AT) gene are frequently detected in breast cancer (BC), with an incidence ranging up to 40%. The mutated form, the Ataxia-telangiectasia mutated (ATM) gene, is involved in cell cycle control, apoptosis, oxidative stress, and telomere maintenance, and its role as a risk factor for cancer development is well established. Recent studies have confirmed that some variants of ATM are associated with an increased risk of BC development and a worse prognosis. Thus, many patients harboring ATM mutations develop intermediate- and high-grade disease, and there is a higher rate of lymph node metastatic involvement. The evidence concerning a correlation of ATM gene mutations and the efficacy of therapeutic strategies in BC management are controversial. -
Predictive Value of RAD51 on the Survival and Drug Responsiveness of Ovarian Cancer Yuchen Feng1, Daoqi Wang2, Luyang Xiong3, Guohua Zhen1 and Jiahong Tan4*
Feng et al. Cancer Cell Int (2021) 21:249 https://doi.org/10.1186/s12935-021-01953-5 Cancer Cell International PRIMARY RESEARCH Open Access Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer Yuchen Feng1, Daoqi Wang2, Luyang Xiong3, Guohua Zhen1 and Jiahong Tan4* Abstract Background: Ovarian cancer has greatly endangered and deteriorated female health conditions worldwide. Refne- ment of predictive biomarkers could enable patient stratifcation and help optimize disease management. Methods: RAD51 expression profle, target-disease associations, and ftness scores of RAD51 were analyzed in ovar- ian cancer using bioinformatic analysis. To further identify its role, gene enrichment analysis was performed, and a regulatory network was constructed. Survival analysis and drug sensitivity assay were performed to evaluate the efect of RAD51 expression on ovarian cancer prognosis. The predictive value of RAD51 was then confrmed in a validation cohort immunohistochemically. Results: Ovarian cancer expressed more RAD51 than normal ovary. RAD51 conferred ovarian cancer dependency and was associated with ovarian cancer. RAD51 had extensive target-disease associations with various diseases, including ovarian cancer. Genes that correlate with and interact with RAD51 were involved in DNA damage repair and drug responsiveness. High RAD51 expression indicated unfavorable survival outcomes and resistance to platinum, taxane, and PARP inhibitors in ovarian cancer. In the validation cohort (126 patients), high RAD51 expression indicated platinum resistance, and platinum-resistant patients expressed more RAD51. Patients with high RAD51 expression had shorter OS (HR 2.968, P < 0.0001) and poorer PFS (HR 2.838, P < 0.0001). RAD51 expression level was negatively cor- related with patients’= survival length. -
About PALB2 Gene Mutations
About PALB2 Gene Mutations About Genes Recommendations Genes are in every cell in our bodies. Genes are made WOMEN of DNA, which gives instructions to cells about how to Starting at age 30: Mammogram and breast MRI every grow and work together. We have two copies of each year (scheduled 6 months apart) gene in each cell—one from our mother and one from our father. When genes work properly, they help stop Some medicines can lower the risk of getting breast cancer from developing. cancer. Surgery to remove both breasts may be an option for some women who have a strong family history of When it works right, the PALB2 gene works together breast cancer. with the BRCA1 and BRCA2 genes to help prevent WOMEN AND MEN cancer. Sometimes changes to the PALB2 gene happen. These changes are called mutations. Mutations can make Screening for pancreatic cancer has benefits and the PALB2 gene stop working and raise the risk for limitations. We do not recommend this screening for certain types of cancer. most people with PALB2 mutations. People who have a PALB2 mutation and a family history of pancreatic Having a mutation in the PALB2 gene makes your risk cancer should ask their doctor or genetic counselor for of getting breast and pancreatic cancers higher than more information. average. The risks for other cancers may also go up with KIDS AND SIBLINGS PALB2 mutations. Researchers are studying the PALB2 gene to understand more. Children and siblings of people with a PALB2 mutation have a 1 in 2 chance of also having the mutation. -
Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer
cancers Article Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer Wojciech Klu´zniak 1, Dominika Wokołorczyk 1, Bogna Rusak 1, Tomasz Huzarski 1,2, Aniruddh Kashyap 1, Klaudia Stempa 1 , Helena Rudnicka 1, Anna Jakubowska 1,3 , Marek Szwiec 4, Sylwia Morawska 1, Katarzyna Gliniewicz 1, Karina Mordak 1, Małgorzata Stawicka 2, Joanna Jarkiewicz-Tretyn 5, Magdalena Cechowska 5, Paweł Domagała 6, Tadeusz D˛ebniak 1, Marcin Lener 1, Jacek Gronwald 1, Jan Lubi ´nski 1, Steven A. Narod 7,8, Mohammad R. Akbari 7,8, Cezary Cybulski 1,* and the Polish Hereditary Breast Cancer Consortium y 1 International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] (W.K.); [email protected] (D.W.); [email protected] (B.R.); [email protected] (T.H.); [email protected] (A.K.); [email protected] (K.S.); [email protected] (H.R.); [email protected] (A.J.); [email protected] (S.M.); [email protected] (K.G.); [email protected] (K.M.); [email protected] (T.D.); [email protected] (M.L.); [email protected] (J.G.); [email protected] (J.L.) 2 Department of Clinical Genetics and Pathology, University of Zielona Góra, 65-046 Zielona Góra, Poland; [email protected] 3 Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland 4 Department of Surgery and Oncology, University of Zielona Góra, 65-046 Zielona Góra, Poland; [email protected] -
The Bloom Syndrome Protein Limits the Lethality Associated with RAD51 Deficiency
Published OnlineFirst March 9, 2010; DOI: 10.1158/1541-7786.MCR-09-0534 Molecular DNA Damage and Cellular Stress Responses Cancer Research The Bloom Syndrome Protein Limits the Lethality Associated with RAD51 Deficiency Kenza Lahkim Bennani-Belhaj1,2, Sébastien Rouzeau1,2, Géraldine Buhagiar-Labarchède1,2, Pauline Chabosseau1,2, Rosine Onclercq-Delic1,2, Emilie Bayart1, Fabrice Cordelières3,4, Jérôme Couturier5,6, and Mounira Amor-Guéret1,2 Abstract Little is known about the functional interaction between the Bloom's syndrome protein (BLM) and the re- combinase RAD51 within cells. Using RNA interference technology, we provide the first demonstration that RAD51 acts upstream from BLM to prevent anaphase bridge formation. RAD51 downregulation was associated with an increase in the frequency of BLM-positive anaphase bridges, but not of BLM-associated ultrafine bridges. Time-lapse live microscopy analysis of anaphase bridge cells revealed that BLM promoted cell survival in the absence of Rad51. Our results directly implicate BLM in limiting the lethality associated with RAD51 deficiency through the processing of anaphase bridges resulting from the RAD51 defect. These findings provide insight into the molecular basis of some cancers possibly associated with variants of the RAD51 gene family. Mol Cancer Res; 8(3); 385–94. ©2010 AACR. Introduction cently, SUMOylation of BLM has been shown to regulate its association with RAD51 and its function in HR-medi- Bloom's syndrome displays one of the strongest known ated repair of damaged replication forks (13). In several correlations between chromosomal instability and a high models, it has been proposed that BLM restarts replication risk of cancer at an early age. -
FANCJ Regulates the Stability of FANCD2/FANCI Proteins and Protects Them from Proteasome and Caspase-3 Dependent Degradation
FANCJ regulates the stability of FANCD2/FANCI proteins and protects them from proteasome and caspase-3 dependent degradation Komaraiah Palle, Ph.D. (Kumar) Assistant Professor of Oncologic Sciences Abraham Mitchell Cancer Research Scholar Mitchell Cancer Institute University of South Alabama Outline • Fanconi anemia (FA) pathway • Role of FA pathway in Genome maintenance • FANCJ and FANCD2 functional relationship • FANCJ-mediated DDR in response to Fork-stalling Fanconi Anemia • Rare, inherited blood disorder. • 1:130,000 births Guido Fanconi 1892-1979 • Affects men and women equally. • Affects all racial and ethnic groups – higher incidence in Ashkenazi Jews and Afrikaners Birth Defects Fanconi anemia pathway • FA is a rare chromosome instability syndrome • Autosomal recessive disorder (or X-linked) • Developmental abnormalities • 17 complementation groups identified to date • FA pathway is involved in DNA repair • Increased cancer susceptibility - many patients develop AML - in adults solid tumors Fanconi Anemia is an aplastic anemia FA patients are prone to multiple types of solid tumors • Increased incidence and earlier onset cancers: oral cavity, GI and genital and reproductive tract head and neck breast esophagus skin liver brain Why? FA is a DNA repair disorder • FA caused by mutations in 17 genes: FANCA FANCF FANCM FANCB FANCG/XRCC9 FANCN/PALB2 FANCC FANCI RAD51C/FANCO FANCD1/BRCA2 FANCJ SLX4/FANCP FANCD2 FANCL ERCC2/XPF/FANCQ FANCE BRCA1/FANCS • FA genes function in DNA repair processes • FA patient cells are highly sensitive -
Mutations in the RAD54 Recombination Gene in Primary Cancers
Oncogene (1999) 18, 3427 ± 3430 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $12.00 http://www.stockton-press.co.uk/onc SHORT REPORT Mutations in the RAD54 recombination gene in primary cancers Masahiro Matsuda1,4, Kiyoshi Miyagawa*,1,2, Mamoru Takahashi2,4, Toshikatsu Fukuda1,4, Tsuyoshi Kataoka4, Toshimasa Asahara4, Hiroki Inui5, Masahiro Watatani5, Masayuki Yasutomi5, Nanao Kamada3, Kiyohiko Dohi4 and Kenji Kamiya2 1Department of Molecular Pathology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Hiroshima 734, Japan; 2Department of Developmental Biology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Hiroshima 734, Japan; 3Department of Cancer Cytogenetics, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Hiroshima 734, Japan; 42nd Department of Surgery, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan; 51st Department of Surgery, Kinki University School of Medicine, 377-2 Ohno-higashi, Osaka-sayama, Osaka 589, Japan Association of a recombinational repair protein RAD51 therefore, probable that members of the RAD52 with tumor suppressors BRCA1 and BRCA2 suggests epistasis group are altered in cancer. that defects in homologous recombination are responsible To investigate whether RAD54, a member of the for tumor formation. Also recent ®ndings that a protein RAD52 epistasis group, is mutated in human cancer, associated with the MRE11/RAD50 repair complex is we performed SSCP analysis and direct sequencing of mutated in Nijmegen breakage syndrome characterized PCR products using mRNAs from 132 unselected by increased cancer incidence and ionizing radiation primary tumors including 95 breast cancers, 13 sensitivity strongly support this idea.